# US 2022/0387458 A1 · Methods of manufacturing microspheres

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0387458 A1
- Document ID: US20220387458A1
- Status: Published application
- Kind: A1
- Application number: 17/879,285
- Filed: 2022-08-02
- Published: 2022-12-08
- Earliest claimed: 2020-01-28
- Assignees: Applaud Medical, Inc.
- Applicants: Applaud Medical, Inc.
- Inventors: Daniel J. Laser; Alice Luong; Robert G. Miotke
- Web page: https://patentgrep.com/patent/US20220387458A1

## CPC

- A61K 31/685: one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
- A61K 9/0034: {Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants}
- A61K 9/167: {with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface (with further drug-free outer coating A61K9/5073)}
- A61K 9/5015: {Organic compounds, e.g. fats, sugars}
- A61K 9/5089: {Processes}
- A61K 41/0028: {Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds}
- A61K 47/06: Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/32: Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone}
- A61K 47/544: {Phospholipids}
- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61K 47/6925: {the form being a microcapsule, nanocapsule, microbubble or nanobubble}
- A61P 13/04: for urolithiasis
- C07F 9/3873: {containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)}
- C07F 9/405: {containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)}
- A61K 31/663: Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)

## Abstract

The present disclosure provides phospholipid-containing compounds, pharmaceutical compositions and microspheres that exhibit high affinity for mineralized metals. The present disclosure also provides strategies for using said compounds, compositions and microspheres in the treatment of nephrolithiasis or kidney stone disease, and methods of manufacturing and preparing said compounds and compositions.

## Claims

### Claim 1

A method of manufacturing microspheres, the method comprising:
(a) preparing a formulation for making microspheres comprising at least one of:
i. a compound of Formula I
or a salt, isomer, or salt of an isomer thereof;
ii. a compound of Formula II
or a salt, isomer, or salt of an isomer thereof; and
iii. a compound of Formula III
or a salt, isomer, or salt of an isomer thereof;
wherein:
n is from 10 to 30,
m is from 1 to 100,
t is from 10 to 30,
y is from 1 to 100,
z is from 10 to 30, and
X is selected from the group consisting of: hydrogen, silyl, acyl, aminoacyl, thioacyl, aminocarbonyl, aminoacyl carbonyloxy, aminothiocarbonyl, aminosulfonyl, amidino, substituted sulfonyl, substituted sulfinyl, carboxy ester, phthalimido, OH, SO3H and PO3H; and
optionally further comprising at least one pharmaceutically acceptable excipient and/or water.

### Claim 2 (depends on 1)

The method of claim 1, further comprising the steps of:
(b) combining in a vessel (i) the formulation of step (a) and (ii) a fluid having a normal boiling point of less than 30° C.; and
(c) agitating the vessel containing the formulation and fluid from step (b);
(d) obtaining the produced microspheres.

### Claim 3 (depends on 2)

The method of claim 2, further comprising the step of:
(e) processing the microsphere solution from step (c) to lengthen its shelf life or to expand the range of environmental conditions tolerated for storage.

### Claim 4 (depends on 2)

The method of claim 2, further comprising:
(f) stoppering the vessel comprising the microspheres from step (c) or (d), optionally under vacuum.

### Claim 5 (depends on 1)

The method of claim 1, wherein the formulation of step (a) is filtered prior to step (b).

### Claim 6 (depends on 3)

The method of claim 3, wherein the processing step (e) is lyophilizing the microsphere solution.

### Claim 7 (depends on 2)

The method of claim 2, wherein the vessel is a unit dosage container.

### Claim 8 (depends on 2)

The method of claim 2, wherein the fluid is n-decafluorobutane.

### Claim 9 (depends on 4)

The method of claim 4, wherein the headspace of the stoppered vessel is filled with n-decafluorobutane.

### Claim 10 (depends on 2)

The method of claim 2, wherein the mean diameter of the microspheres from step (c) is about 0.1 to 1000 μm, about 0.1 to 100 μm, about 0.1 to 30 μm, or about 0.7 to 10 μm.

### Claim 11 (depends on 6)

The method of claim 6, wherein the loss of microspheres during lyophilization is no more than 25%, no more than 15% or no more than 10%.

### Claim 12 (depends on 1)

The method of claim 1, wherein the molecular weight of the compound of Formula I is from about 1,500 to about 5,000 Daltons, about 3200 Daltons, about 2800 Daltons or about 790 Daltons; wherein the molecular weight of the compound of Formula II is from about 1,500 to about 5,000 Daltons; and/or wherein the molecular weight of the compound of Formula III is from about 500 to about 2,000 Daltons.

### Claim 13 (depends on 1)

The method of claim 1, wherein the molar ratio of the compound of Formula I to the compound of Formula II in the formulation ranges from 1:100 to 1:1; and/or wherein the molar ratio of the compound of Formula II to the compound of Formula III in the formulation ranges from 1:20 to 1:8.

### Claim 14 (depends on 2)

The method of claim 2, wherein the microspheres from step (c) comprise at least one of: 0.01-5 mol % of a compound of Formula I; 5-9.9 mol % of a compound of Formula II; and 80-95 mol % of the compound of Formula III.

### Claim 15 (depends on 2)

The method of claim 2, wherein the microspheres from step (c) comprise at least one of: no more than 5 mol % of the compound of Formula I; no more than 10 mol % of the compound of Formula II; and no more than 95 mol % of the compound of Formula III.

### Claim 16 (depends on 1)

The method of claim 1, wherein:
the compound of Formula I is a compound of Formula Ib
the compound of Formula II is a compound of Formula IIb
and/or
the compound of Formula III is the compound of Formula IIIa

### Claim 17 (depends on 2)

The method of claim 2, wherein:
the compound of Formula I is a compound of Formula Ib
the compound of Formula II is a compound of Formula IIb
and/or
the compound of Formula III is the compound of Formula IIIa; and wherein the molar ratio of the compound of Formula Ib to the compound of Formula IIb in the microspheres from step (c) ranges from 1:100 to 1:1; and/or wherein the molar ratio of the compound of Formula IIb to the compound of Formula IIIa in the microspheres from step (c) ranges from 1:20 to 1:8.

### Claim 18

A method of reconstituting microspheres, wherein the method comprises the steps of:
(a) obtaining a unit dosage vessel comprising a pharmaceutical composition comprising a therapeutically effective amount of a microsphere composition and optionally, at least one pharmaceutically acceptable excipient; wherein the microsphere composition comprises at least one of:
i. a compound of Formula I
or a salt, isomer, or salt of an isomer thereof;
ii. a compound of Formula II
or a salt, isomer, or salt of an isomer thereof; and
iii. a compound of Formula III
or a salt, isomer, or salt of an isomer thereof;
wherein:
n is from 10 to 30;
m is from 1 to 100;
tis from 10 to 30;
y is from 1 to 100;
z is from 10 to 30; and
X is selected from the group consisting of: hydrogen, silyl, acyl, aminoacyl, thioacyl, aminocarbonyl, aminoacyl carbonyloxy, aminothiocarbonyl, aminosulfonyl, amidino, substituted sulfonyl, substituted sulfinyl, carboxy ester, phthalimido, OH, SO3H and PO3H;
(b) adding a sufficient amount of water or a saline solution to the vessel,
(c) optionally, adding a volume of a fluid having a normal boiling point of less than 30° C. to the vessel of step (a); and
(d) optionally shaking the container of step (a) or step (b); wherein the shaking of the container optionally lasts no more than 180 seconds.

### Claim 19 (depends on 18)

The method of claim 18, wherein the method further comprises a step of filling the vessel with gas before step (a).

### Claim 20 (depends on 18)

The method of claim 18, wherein the amount of water or the saline solution is no more than 100 milliliters; optionally wherein the amount of the water or the saline solution added is sufficient to produce a homogeneous mixture comprising the reconstituted microspheres.
